Journal
Clinical cancer research
Publication Date
3-1-2022
Volume
28
Issue
5
First Page
903
Last Page
914
Document Type
Open Access Publication
DOI
10.1158/1078-0432.CCR-21-2547
Rights and Permissions
Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EEW, Coussens LM. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clin Cancer Res. 2022 Mar 1;28(5):903-914. doi.org/10.1158/1078-0432.CCR-21-2547 This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 International (CC BY-NC-ND)
Recommended Citation
Taylor, Matthew H; Betts, Courtney B; Maloney, Lauren; Nadler, Eric; Algazi, Alain; Guarino, Michael J; Nemunaitis, John; Jimeno, Antonio; Patel, Priti; Munugalavadla, Veerendra; Tao, Lin; Adkins, Douglas; Goldschmidt, Jerome H; Cohen, Ezra E W; and Coussens, Lisa M, "Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: Phase 2 proof-of-concept study." Clinical cancer research. 28, 5. 903 - 914. (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11625
